Fig. 4From: A randomized, double-blind, placebo-controlled 12-week trial of infliximab in patients with juvenile-onset spondyloarthritisPercentage of patients reaching the American College of Rheumatology (ACR) Paediatric 30 (Pedi 30), 50, 70, 90, and 100 response criteria per treatment group at week 12 (end RCT phase)Back to article page